Drug intelligence / Profile preview

Abera Bioscience Tuberculosis Vaccine

Development stage: Preclinical
Lead developer: Abera Bioscience
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Abera Bioscience is developing an intranasal vaccine candidate for the prevention of tuberculosis (TB). The vaccine utilizes the company's proprietary Outer Membrane Vesicle (OMV) platform to present *Mycobacterium tuberculosis* antigens to the immune system. This mucosal delivery approach is designed to induce both local mucosal immunity in the respiratory tract—the primary entry point for TB—and systemic immunity. By leveraging the OMV technology, the vaccine aims to provide a robust immune response against TB antigens. The program is currently in the early stages of preclinical development.

Other names: OMV-based Tuberculosis Vaccine

Beyond the preview

Go deeper on Abera Bioscience Tuberculosis Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abera Bioscience Tuberculosis Vaccine.

Explore the full profile